Keywords: AstraZeneca, MedImmune, Phylogica, Antimicrobila peptides, Licensing

AstraZeneca’s MedImmune unit in licensing deal with Phylogica for antimicrobial peptide

Article | 20 August 2010

Print This

Australian drug discovery firm Phylogica (ASX: PYC, XETRA: PH7) has entered into an agreement with Anglo-Swedish drug major AstraZeneca’s ( ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in